Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

Respiratory Research
Anthony D D'UrzoAUGMENT COPD study investigators

Abstract

Combining two long-acting bronchodilators with complementary mechanisms of action may provide treatment benefits to patients with chronic obstructive pulmonary disease (COPD) that are greater than those derived from either treatment alone. The efficacy and safety of a fixed-dose combination (FDC) of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol fumarate, a long-acting β2-agonist, in patients with moderate to severe COPD are presented. In this 24-week double-blind study, 1692 patients with stable COPD were equally randomized to twice-daily treatment with FDC aclidinium 400 μg/formoterol 12 μg (ACL400/FOR12 FDC), FDC aclidinium 400 μg/formoterol 6 μg (ACL400/FOR6 FDC), aclidinium 400 μg, formoterol 12 μg, or placebo administered by a multidose dry powder inhaler (Genuair®/Pressair®)*. Coprimary endpoints were change from baseline to week 24 in 1-hour morning postdose FEV1 (FDCs versus aclidinium) and change from baseline to week 24 in morning predose (trough) FEV1 (FDCs versus formoterol). Secondary endpoints were change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score and improvement in Transition Dyspnea Index (TDI) focal score at week 24. Safety and tolerability were also ass...Continue Reading

References

Dec 4, 2003·Pulmonary Pharmacology & Therapeutics·Mario CazzolaStefano Centanni
Aug 2, 2005·The European Respiratory Journal·J A van NoordP J G Cornelissen
Aug 2, 2005·The European Respiratory Journal·M R MillerUNKNOWN ATS/ERS Task Force
Oct 4, 2005·Respiratory Medicine·Malcolm CampbellKlaus F Rabe
Mar 15, 2006·Respiration; International Review of Thoracic Diseases·Kai RichterHelgo Magnussen
Dec 2, 2006·COPD·Paul W Jones
Aug 30, 2008·Thorax·J Bourbeau, S J Bartlett
Feb 21, 2009·COPD·Donald P TashkinSantosh T Varghese
Jul 3, 2009·Current Medical Research and Opinion·Martyn R PartridgeIain R Small
Apr 13, 2010·Pulmonary Pharmacology & Therapeutics·Mario Cazzola, Mathieu Molimard
Dec 9, 2010·Respirology : Official Journal of the Asian Pacific Society of Respirology·Jianmiao WangWeining Xiong
Sep 2, 2011·European Respiratory Review : an Official Journal of the European Respiratory Society·A AgustiS Rennard
Mar 24, 2012·The European Respiratory Journal·Paul W JonesEsther Garcia Gil
Aug 11, 2012·American Journal of Respiratory and Critical Care Medicine·Jørgen VestboRoberto Rodriguez-Roisin
Aug 7, 2013·Respiratory Medicine·Arthur F GelbUNKNOWN LAS-MD-35 study investigators
Nov 2, 2013·The European Respiratory Journal·Donald A MahlerDonald Banerji
Dec 19, 2013·International Journal of Chronic Obstructive Pulmonary Disease·David PriceJordi Estruch
Jan 5, 2014·American Journal of Respiratory and Critical Care Medicine·Paul W JonesJadwiga A Wedzicha

❮ Previous
Next ❯

Citations

Sep 15, 2015·Expert Review of Respiratory Medicine·Tony D'UrzoEdward Kerwin
May 3, 2016·Expert Review of Respiratory Medicine·Konstantinos KostikasFrancesco Patalano
Jan 23, 2016·The Lancet. Respiratory Medicine·Lies LahousseGuy G Brusselle
Mar 11, 2017·Expert Review of Respiratory Medicine·Amanda R van BuulChristian Taube
Apr 12, 2017·Postgraduate Medicine·Nicola A HananiaBarbara P Yawn
Feb 27, 2017·NPJ Primary Care Respiratory Medicine·Anthony D'UrzoEsther Garcia Gil
Mar 28, 2017·Respiratory Medicine·Fabiano Di MarcoAngelo Guido Corsico
Jun 28, 2017·Respirology : Official Journal of the Asian Pacific Society of Respirology·Wang-Chun ChenYu-Feng Wei
Apr 5, 2018·Expert Opinion on Drug Discovery·Mario MalerbaPaolo Montuschi
Nov 9, 2017·Expert Opinion on Pharmacotherapy·Chitra Lal, Charlie Strange
Sep 23, 2014·The Cochrane Database of Systematic Reviews·Han NiSoe Moe
May 3, 2018·Expert Opinion on Drug Safety·Paola RoglianiLuigino Calzetta
Apr 15, 2018·Clinical Drug Investigation·Margarita CapelItziar Oyagüez
Jan 20, 2015·Expert Opinion on Pharmacotherapy·Chitra Lal, Charlie Strange
Dec 12, 2018·The Cochrane Database of Systematic Reviews·Han NiK Neelakantan Viswanathan
Feb 2, 2019·Expert Opinion on Pharmacotherapy·Paola RoglianiJosuel Ora
Jan 18, 2017·European Respiratory Review : an Official Journal of the European Respiratory Society·Luigino CalzettaMaria Gabriella Matera
Aug 6, 2016·The European Respiratory Journal·Claus VogelmeierAnne Leselbaum
May 18, 2019·Therapeutic Advances in Respiratory Disease·Anthony D D'UrzoKenneth R Chapman
Jun 22, 2017·Respiratory Research·Marc MiravitllesJosé R Jardim
Jan 28, 2016·Current Opinion in Pulmonary Medicine·Hetal J Patel
Feb 23, 2020·NPJ Primary Care Respiratory Medicine·Ioanna Tsiligianni, Janwillem W H Kocks
Dec 20, 2019·Postgraduate Medicine·G HillasA I Papaioannou
Mar 1, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Maria Gabriella MateraMario Cazzola
Jun 26, 2015·Expert Review of Clinical Pharmacology·Andrea S Melani

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01437397

Related Concepts

Related Feeds

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.